Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
Pfizer presented robust Phase 2b data for berobenatide, an investigational monthly GLP-1 receptor agonist, at the ADA Scientific Sessions. The VESPER-1 study showed a non-placebo-adjusted weight loss of 15.9% with no plateau at 32 weeks, while VESPER-2 demonstrated a 2.2% reduction in HbA1c in patients with type 2 diabetes.
Key figures
- Drug Name
- berobenatide (PF’3944)
- Phase Of Trial
- Phase 2b
- Hba1c reduction
- 2.2%
- Weight loss percent
- 15.9%
- Total obesity trials
- 20+
- Planned phase3 trials
- 10
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.